| Literature DB >> 32259783 |
William J Gradishar1, Benjamin O Anderson2, Jame Abraham3, Rebecca Aft4, Doreen Agnese5, Kimberly H Allison6, Sarah L Blair7, Harold J Burstein8, Chau Dang9, Anthony D Elias10, Sharon H Giordano11, Matthew P Goetz12, Lori J Goldstein13, Steven J Isakoff14, Jairam Krishnamurthy15, Janice Lyons3, P Kelly Marcom16, Jennifer Matro17, Ingrid A Mayer18, Meena S Moran19, Joanne Mortimer20, Ruth M O'Regan21, Sameer A Patel13, Lori J Pierce22, Hope S Rugo23, Amy Sitapati7, Karen Lisa Smith24, Mary Lou Smith25, Hatem Soliman26, Erica M Stringer-Reasor27, Melinda L Telli6, John H Ward28, Jessica S Young29, Jennifer L Burns30, Rashmi Kumar30.
Abstract
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.Entities:
Mesh：
Year: 2020 PMID： 32259783 DOI： 10.6004/jnccn.2020.0016
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908